Abstract
Angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin II type‑1 receptor blockers (ARBs) are among the most widely prescribed drugs for the treatment of arterial hypertension, heart failure and chronic kidney disease. A number of studies, mainly in animals and not involving the lungs, have indicated that these drugs can increase expression of angiotensin-converting enzyme 2 (ACE2). ACE2 is the cell entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) that is currently battering the globe. This has led to the hypothesis that use of ACEIs and ARBs may increase the risk of developing severe COVID-19. In this point of view paper, possible scenarios regarding the impact of ACEI/ARB pharmacotherapy on COVID-19 are discussed in relation to the currently available evidence. Although further research on the influence of blood-pressure-lowering drugs, including those not targeting the renin-angiotensin system, is warranted, there are presently no compelling clinical data showing that ACEIs and ARBs increase the likelihood of contracting COVID-19 or worsen the outcome of SARS-CoV‑2 infections. Thus, unless contraindicated, use of ACEIs/A...Continue Reading
References
May 14, 2004·The Journal of Pathology·I HammingH van Goor
Jul 12, 2005·Nature Medicine·Keiji KubaJosef M Penninger
Jan 19, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Keiji KubaJosef M Penninger
May 22, 2016·European Heart Journal·Piotr PonikowskiUNKNOWN ESC Scientific Document Group
Oct 5, 2016·Hypertension·Ségolène GalandrinCéline Galés
Apr 30, 2017·Circulation·Clyde W YancyCheryl Westlake
Dec 31, 2017·Current Opinion in Pharmacology·Wan Shun Daniel TanWai-Shiu Fred Wong
Jun 7, 2018·Physiological Reviews·Steven J ForresterSatoru Eguchi
Apr 6, 2019·Proceedings·Christopher HenryHeath D White
Aug 4, 2019·Pulmonary Pharmacology & Therapeutics·Di WangShan-Shan Hu
Sep 21, 2019·Pharmacological Reviews·Lauren B ArendseEdward D Sturrock
Jan 25, 2020·The New England Journal of Medicine·Na ZhuUNKNOWN China Novel Coronavirus Investigating and Research Team
Jan 28, 2020·Lancet·Jasper Fuk-Woo ChanKwok-Yung Yuen
Feb 13, 2020·Science China. Life Sciences·Yingxia LiuLei Liu
Feb 23, 2020·The Lancet Infectious Diseases·Ensheng DongLauren Gardner
Mar 7, 2020·Cell·Markus HoffmannStefan Pöhlmann
Mar 1, 2010·Future Virology·Brigitte A Wevers, Lia van der Hoek
Apr 1, 2020·The New England Journal of Medicine·Muthiah VaduganathanScott D Solomon
Apr 2, 2020·Emerging Microbes & Infections·Juan MengGuoliang Zhang
Apr 16, 2020·Cardiovascular Research·Reinhold KreutzMichel Burnier
Apr 18, 2020·Circulation Research·Peng ZhangHongliang Li
Apr 24, 2020·JAMA Cardiology·Juyi LiAiping Deng
May 2, 2020·The New England Journal of Medicine·Mandeep R MehraAmit N Patel
May 2, 2020·The New England Journal of Medicine·Giuseppe ManciaGiovanni Corrao
May 2, 2020·The New England Journal of Medicine·Harmony R ReynoldsJudith S Hochman
Citations
Aug 26, 2020·Cellular and Molecular Neurobiology·Walter J LukiwJames M Hill
Sep 14, 2020·Thrombosis and Haemostasis·Grigoris T GerotziafasUNKNOWN Scientific Reviewer Committee
Jul 18, 2020·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·J Vendrik, J J Piek
Jul 17, 2020·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·A A F de Vries
Aug 31, 2020·Immunology and Cell Biology·Shahin HallajFarhad Jadidi-Niaragh
Oct 17, 2020·Clinical Science·Carlos M FerrarioLeanne Groban
Oct 24, 2020·Journal of Medical Virology·Yixuan WangQingsong Qin
Dec 1, 2020·Drug Development Research·Fatemeh BabaeiHossein Hosseinzadeh
Mar 25, 2021·Curēus·Gagandeep KaurGunjan Gupta
Dec 24, 2020·Expert Review of Anti-infective Therapy·Md Jamal Hossain, S M Abdur Rahman